Skip to main content
. 2023 Jul;27(7):517–521. doi: 10.5005/jp-journals-10071-24482

Table 3.

Adverse events

Variables Control (n = 21) Intervenção (n = 19) p
Arrhitmia, n (%) 3 (14.3) 3 (15.8) 1.000
Seizure, n (%) 0 1 (5.3) 0.475
Vomiting, n (%) 2 (9.5) 2 (10.5) 1.000
Constipation, n (%) 14 (66.7) 13 (68.4) 1.000

Cholestasis, agranulocytosis, thrombocytopenia, hepatitis and diplopia were not observed in any patients